Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502).
Weickhardt A, Foroudi F, Lawrentschuk N, Xie J, Sidhom M, Pal A, Grimison P, Zhang A, Ng S, Tang C, Hovey E, Chen C, Hruby G, Guminski A, McJannett M, Conduit C, Tran B, Davis ID, Hayne D. Weickhardt A, et al. Among authors: grimison p. Eur Urol Oncol. 2024 Jun;7(3):469-477. doi: 10.1016/j.euo.2023.09.011. Epub 2023 Oct 7. Eur Urol Oncol. 2024. PMID: 37806844 Clinical Trial.
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.
Bendell J, LoRusso P, Overman M, Noonan AM, Kim DW, Strickler JH, Kim SW, Clarke S, George TJ, Grimison PS, Barve M, Amin M, Desai J, Wise-Draper T, Eck S, Jiang Y, Khan AA, Wu Y, Martin P, Cooper ZA, Elgeioushi N, Mueller N, Kumar R, Patel SP. Bendell J, et al. Among authors: grimison ps. Cancer Immunol Immunother. 2023 Jul;72(7):2443-2458. doi: 10.1007/s00262-023-03430-6. Epub 2023 Apr 5. Cancer Immunol Immunother. 2023. PMID: 37016126 Free PMC article. Clinical Trial.
Deriving a preference-based utility measure for cancer patients from the European Organisation for the Research and Treatment of Cancer's Quality of Life Questionnaire C30: a confirmatory versus exploratory approach.
Costa DS, Aaronson NK, Fayers PM, Grimison PS, Janda M, Pallant JF, Rowen D, Velikova G, Viney R, Young TA, King MT. Costa DS, et al. Patient Relat Outcome Meas. 2014 Nov 6;5:119-29. doi: 10.2147/PROM.S68776. eCollection 2014. Patient Relat Outcome Meas. 2014. PMID: 25395875 Free PMC article.
The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study.
Smith AB, Butow P, Olver I, Luckett T, Grimison P, Toner GC, Stockler MR, Hovey E, Stubbs J, Turner S, Hruby G, Gurney H, Alam M, Cox K, King MT. Smith AB, et al. Among authors: grimison p. J Cancer Surviv. 2016 Apr;10(2):223-33. doi: 10.1007/s11764-015-0468-5. Epub 2015 Jul 16. J Cancer Surviv. 2016. PMID: 26178326
Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30.
King MT, Viney R, Simon Pickard A, Rowen D, Aaronson NK, Brazier JE, Cella D, Costa DSJ, Fayers PM, Kemmler G, McTaggart-Cowen H, Mercieca-Bebber R, Peacock S, Street DJ, Young TA, Norman R; MAUCa Consortium. King MT, et al. Pharmacoeconomics. 2018 Feb;36(2):225-238. doi: 10.1007/s40273-017-0582-5. Pharmacoeconomics. 2018. PMID: 29270835 Free PMC article.
The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Development and Australian Value Set.
King MT, Norman R, Mercieca-Bebber R, Costa DSJ, McTaggart-Cowan H, Peacock S, Janda M, Müller F, Viney R, Pickard AS, Cella D; Multi-Attribute Utility in Cancer Consortium. King MT, et al. Value Health. 2021 Jun;24(6):862-873. doi: 10.1016/j.jval.2021.01.007. Epub 2021 May 7. Value Health. 2021. PMID: 34119085 Free article.
125 results